Role of diffusion-weighted imaging in monitoring treatment response following high-intensity focused ultrasound ablation of recurrent sacral chordoma

Madhurima R Chetan, Paul C Lyon, Feng Wu, Rachel Phillips, David Cranston, Martin J Gillies, Stana Bojanic, Madhurima R Chetan, Paul C Lyon, Feng Wu, Rachel Phillips, David Cranston, Martin J Gillies, Stana Bojanic

Abstract

Chordoma is the most common malignant tumor of the sacrum and is associated with significant neurologic morbidity. Local recurrence is very common, and the long-term prognosis is poor. High-intensity focused ultrasound (HIFU) is a noninvasive and nonionising ablative therapy that has been successful in treating other tumor types and is being evaluated as a new therapy for sacral chordoma. Contrast-enhanced magnetic resonance imaging is typically used to evaluate tumor perfusion following HIFU; however, its utility is limited in poorly perfused tumors. Diffusion-weighted imaging (DWI) provides tissue contrast based on differences in the diffusion of extracellular water without using gadolinium-based contrast agents. We present novel DWI findings following a planned partial HIFU ablation of a large sacral chordoma which had recurred after radiotherapy. Following HIFU, the treated tumor volume demonstrated loss of restriction on DWI correlating with photopenia on positron emission tomography. This suggests successful ablation and tumor necrosis. This novel finding may provide guidance for sequence selection when evaluating HIFU therapy for sacral chordoma and other tumor types for which contrast-enhanced magnetic resonance imaging may have limited utility.

Keywords: Ablative therapy; Focused ultrasound; High-intensity focused ultrasound; Sacral chordoma; Therapeutic ultrasound.

Figures

Fig. 1
Fig. 1
MRI prior to HIFU treatment (top row) and at 1 month (middle row) and 8 months (bottom row) after HIFU treatment. Left column: axial T1-weighted fat-suppressed fast-spoiled gradient echo (LAVA) sequence, venous phase imaging. Middle and right columns: axial DWI and ADC map at b = 800 (top row), b = 1000 (middle row), b = 700 (bottom row). ADC values are significantly higher on the HIFU-treated left side of the chordoma than the untreated right side, indicating a reduction in diffusion restriction.
Fig. 2
Fig. 2
Axial ADC map 8 months after HIFU treatment (left) and axial fused 18F-FDG PET/CT 11 months after HIFU treatment (right). The HIFU-treated left side of the chordoma show excellent correlation with high ADC values and no 18F-FDG uptake, indicating tumor necrosis.

References

    1. Yakkioui Y., van Overbeeke J.J., Santegoeds R., van Engeland M., Temel Y. Chordoma: the entity. Biochim Biophys Acta Rev Cancer. 2014;1846:655–669.
    1. Llauger J., Palmer J., Amores S., Bague S., Camins A. Primary tumors of the sacrum. Am J Roentgenol. 2000;174:417–424.
    1. York J.E., Kaczaraj A., Abi-Said D. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74–79. discussion 79-80.
    1. Rotondo R., Folkert W., Liebsch N. High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. J Neurosurg Spine. 2015;23:788–797.
    1. Schulz-Ertner D., Karger C., Feuerhake A. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol. 2007;68:449–457.
    1. Yang Y., Niu X., Li Y., Liu W., Xu H. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute. Eur Spine J. 2017;26:1910–1916.
    1. Radaelli S., Stacchiotti S., Ruggieri P. Sacral chordoma. Spine (Phila. Pa. 1976) 2016;41:1049–1057.
    1. Haar G.ter. Ultrasound bioeffects and safety. Proc Inst Mech Eng Part H J Eng Med. 2010;224:363–373.
    1. Focused Ultrasound Foundation . 2018. State of the Field Report.
    1. Mauri G., Nicosia L., Xu Z. Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer. Br J Radiol. 2018;91
    1. Gillies M.J., Lyon P., Wu F. High-intensity focused ultrasonic ablation of sacral chordoma is feasible: a series of four cases and details of a national clinical trial. Br. J. Neurosurg. 2017;31:446–451.
    1. Layne K.A., Dargan P.I., Archer J.R.H., Wood D.M. Gadolinium deposition and the potential for toxicological sequelae – a literature review of issues surrounding gadolinium based contrast agents. Br J Clin Pharmacol. 2018;84:2522–2534.
    1. Chenevert T., Stegman L., Taylor J. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029–2036.
    1. Koral K., Mathis D., Gimi B. Common pediatric cerebellar tumors: correlation between cell densities and apparent diffusion coefficient metrics. Radiology. 2013;268:532–537.
    1. Bojanic, S.ISRCTN - ISRCTN91527768: Extra-corporeal High Intensity Focused UltraSound for primary Sacrococcygeal bone Tumours.
    1. Burn P., McCall J., Chinn R. Uterine fibroleiomyoma: MR imaging appearances before and after embolization of uterine arteries. Radiology. 2000;214:729–734.
    1. Yeom K., Lober R., Mobley B. Diffusion-weighted MRI: distinction of skull base chordoma from chondrosarcoma. Am J Neuroradiol. 2013;34:1056–1061.
    1. Ochoa-Figueroa M., Martinez-Gimeno E., Allende-Riera A. Role of 18 F-FDG PET-CT in the study of sacrococcygeal chordoma Papel de la 18 F-FDG PET-TC en el estudio del cordoma sacrocoxígeo. Rev Esp Med Nucl Imagen Mol. 2012;31:359–361.
    1. Park S.-A., Kim H.S. F-18 FDG PET/CT evaluation of sacrococcygeal chordoma. Clin Nucl Med. 2008;33:906–908.
    1. Cui F., Su M., Zhang H., Tian R. Humeral metastasis of sacrococcygeal chordoma detected by fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography: a case report. Radiol Case Rep. 2018;13:449–452.
    1. Lin C.Y., Kao C., Liang J. Chordoma detected on F-18 FDG PET. Clin Nucl Med. 2006;31:506–507.
    1. Farsad K., Kattapuram S.V., Sacknoff R., Ono J., Nielsen G.P. Sacral chordoma. RadioGraph. 2009;29:1525–1530.
    1. Anzidei M., Napoli A., Sacconi B. Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome. Radiol Med. 2016;121:905–915.
    1. Jacobs M.A., Herskovits E.H., Kim H.S. Uterine fibroids: diffusion-weighted MR Imaging for monitoring therapy with focused ultrasound surgery—preliminary study. Radiology. 2005;236:196–203.
    1. Zhang Y., Zhao J., Guo D., Zhong W., Ran L. Evaluation of short-term response of high intensity focused ultrasound ablation for primary hepatic carcinoma: utility of contrast-enhanced MRI and diffusion-weighted imaging. Eur. J. Radiol. 2011;79:347–352.
    1. Giles S.L, Winfield J., Collins D. Value of diffusion-weighted imaging for monitoring tissue change during magnetic resonance-guided high-intensity focused ultrasound therapy in bone applications: an ex-vivo study. Eur. Radiol. Exp. 2018;2:10.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit